A specific subset of men with a specific genetic variation respond to non-steroidal CYP17A1 inhibition

Just over a year ago, we reported on a paper by Hearn et al. that had shown that a specific inherited mutation in the HSD3B1 gene seemed to be associated with a more aggressive form of prostate cancer that was less responsive to treatment with androgen deprivation therapy (ADT). … READ MORE …

A new form of chemo-immunotherapy combination works very well — in mice!

Alas, our friends at The Daily Telegraph in the UK seem to have managed to hyperinflate some early scientific findings into an overnight cure for prostate cancer in general and  metastatic, castration-resistant prostate cancer in particular. … READ MORE …

Another drug that works in mice, but don’t hold your breath …

According to a news report in The Daily Telegraph (a British newspaper) today, “Prostate cancer could be ‘switched off’ with injection.” However, the research that stimulated this headline has only been conducted in mice, so there is a long way to go before we know if this is a real possibility in man. … READ MORE …

5α-Reductase-III and its potential in prevention/treatment of prostate cancer

There are in fact three so-called “isozymes” (slightly different versions) of the human enzyme 5α-steroid reductase. The activity of 5α-reductase-II can be affected by the 5α-reductase inhibitor (5-ARI) finasteride (Proscar); the activity of 5α-reductase-I and -II can be affected by the 5-ARI dutasteride (Avodart), but … READ MORE …